Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) EBT: 2020-2024

Historic EBT for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to -$139.4 million.

  • Arcutis Biotherapeutics' EBT rose 118.03% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$43.3 million, marking a year-over-year increase of 77.82%. This contributed to the annual value of -$139.4 million for FY2024, which is 46.19% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported EBT of -$139.4 million as of FY2024, which was up 46.19% from -$259.0 million recorded in FY2023.
  • Arcutis Biotherapeutics' 5-year EBT high stood at -$136.6 million for FY2020, and its period low was -$311.5 million during FY2022.
  • Its 3-year average for EBT is -$236.6 million, with a median of -$259.0 million in 2023.
  • As far as peak fluctuations go, Arcutis Biotherapeutics' EBT plummeted by 51.02% in 2021, and later soared by 46.19% in 2024.
  • Arcutis Biotherapeutics' EBT (Yearly) stood at -$136.6 million in 2020, then slumped by 51.02% to -$206.4 million in 2021, then crashed by 50.93% to -$311.5 million in 2022, then rose by 16.83% to -$259.0 million in 2023, then surged by 46.19% to -$139.4 million in 2024.